Warning letter
Aurobindo Pharmaceutical Limited: warning letter of Jan 12, 2022
FDA warning letter 618091 · Center for Drug Evaluation and Research | CDER
Key facts
| Reference number | 618091 |
|---|---|
| Company | Aurobindo Pharmaceutical Limited |
| Subject | CGMP/Active Pharmaceutical Ingredient (API)/Adulterated |
| Issue date | Jan 12, 2022 |
| Posted date | Jan 25, 2022 |
| Issuing office | Center for Drug Evaluation and Research | CDER |
| Product type | Drugs |
| Inspection city | Sangareddy |
| Inspection start date | Aug 2, 2021 |
| Letter on fda.gov | fda.gov |
At a glance
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: